南新制药，拟重大资产重组！不停牌

Group 1 - The company announced a cash acquisition of assets from Future Pharmaceuticals for no more than 480 million yuan, including three types of microelement injection solutions and related intellectual property [1] - This acquisition is expected to constitute a significant asset restructuring and will not involve share issuance or change in control [1] - The company plans to disclose a formal proposal related to the transaction within six months and will continue to fulfill information disclosure obligations as necessary [1] Group 2 - The acquisition will enrich the company's product pipeline and align with its "health management for all ages" strategy, optimizing its product layout in the "anti-infection - chronic disease - nutritional support" sectors [2] - The microelement injection solutions have already established market sales, which could provide immediate revenue and profit growth for the company, enhancing its operational sustainability and profitability [2] - The acquired assets include a mature national sales channel and academic promotion system, which will help the company expand sales channels for its products, particularly in the pediatric flu medication market [2] Group 3 - The company specializes in antiviral and infectious disease prevention drugs, as well as treatments for major diseases like cancer and cardiovascular diseases [3] - It has developed a combined R&D system for innovative and generic drugs, with a production chain covering over 30 provinces in China [3] - The company reported a revenue of 40.62 million yuan in Q1 2025, a year-on-year decline of 70.21%, with a net loss of 8.03 million yuan [3]